These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 28931654)

  • 1. Cancer immunotherapy with recombinant poliovirus induces IFN-dominant activation of dendritic cells and tumor antigen-specific CTLs.
    Brown MC; Holl EK; Boczkowski D; Dobrikova E; Mosaheb M; Chandramohan V; Bigner DD; Gromeier M; Nair SK
    Sci Transl Med; 2017 Sep; 9(408):. PubMed ID: 28931654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineered Oncolytic Poliovirus PVSRIPO Subverts MDA5-Dependent Innate Immune Responses in Cancer Cells.
    Walton RW; Brown MC; Sacco MT; Gromeier M
    J Virol; 2018 Oct; 92(19):. PubMed ID: 29997212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetically stable poliovirus vectors activate dendritic cells and prime antitumor CD8 T cell immunity.
    Mosaheb MM; Dobrikova EY; Brown MC; Yang Y; Cable J; Okada H; Nair SK; Bigner DD; Ashley DM; Gromeier M
    Nat Commun; 2020 Jan; 11(1):524. PubMed ID: 31988324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant Poliovirus for Cancer Immunotherapy.
    Gromeier M; Nair SK
    Annu Rev Med; 2018 Jan; 69():289-299. PubMed ID: 29414253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant oncolytic poliovirus, PVSRIPO, has potent cytotoxic and innate inflammatory effects, mediating therapy in human breast and prostate cancer xenograft models.
    Holl EK; Brown MC; Boczkowski D; McNamara MA; George DJ; Bigner DD; Gromeier M; Nair SK
    Oncotarget; 2016 Nov; 7(48):79828-79841. PubMed ID: 27806313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy.
    Takeda Y; Kataoka K; Yamagishi J; Ogawa S; Seya T; Matsumoto M
    Cell Rep; 2017 May; 19(9):1874-1887. PubMed ID: 28564605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy.
    Kranz LM; Diken M; Haas H; Kreiter S; Loquai C; Reuter KC; Meng M; Fritz D; Vascotto F; Hefesha H; Grunwitz C; Vormehr M; Hüsemann Y; Selmi A; Kuhn AN; Buck J; Derhovanessian E; Rae R; Attig S; Diekmann J; Jabulowsky RA; Heesch S; Hassel J; Langguth P; Grabbe S; Huber C; Türeci Ö; Sahin U
    Nature; 2016 Jun; 534(7607):396-401. PubMed ID: 27281205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recurrent Glioblastoma Treated with Recombinant Poliovirus.
    Desjardins A; Gromeier M; Herndon JE; Beaubier N; Bolognesi DP; Friedman AH; Friedman HS; McSherry F; Muscat AM; Nair S; Peters KB; Randazzo D; Sampson JH; Vlahovic G; Harrison WT; McLendon RE; Ashley D; Bigner DD
    N Engl J Med; 2018 Jul; 379(2):150-161. PubMed ID: 29943666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I trial of intratumoral PVSRIPO in patients with unresectable, treatment-refractory melanoma.
    Beasley GM; Nair SK; Farrow NE; Landa K; Selim MA; Wiggs CA; Jung SH; Bigner DD; True Kelly A; Gromeier M; Salama AK
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33875611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intralymphatic dendritic cell vaccination induces tumor antigen-specific, skin-homing T lymphocytes.
    Grover A; Kim GJ; Lizée G; Tschoi M; Wang G; Wunderlich JR; Rosenberg SA; Hwang ST; Hwu P
    Clin Cancer Res; 2006 Oct; 12(19):5801-8. PubMed ID: 17020987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potentiating Oncolytic Virus-Induced Immune-Mediated Tumor Cell Killing Using Histone Deacetylase Inhibition.
    Jennings VA; Scott GB; Rose AMS; Scott KJ; Migneco G; Keller B; Reilly K; Donnelly O; Peach H; Dewar D; Harrington KJ; Pandha H; Samson A; Vile RG; Melcher AA; Errington-Mais F
    Mol Ther; 2019 Jun; 27(6):1139-1152. PubMed ID: 31053413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploiting Preexisting Immunity to Enhance Oncolytic Cancer Immunotherapy.
    Tähtinen S; Feola S; Capasso C; Laustio N; Groeneveldt C; Ylösmäki EO; Ylösmäki L; Martins B; Fusciello M; Medeot M; Tagliamonte M; Chiaro J; Hamdan F; Peltonen K; Ranki T; Buonaguro L; Cerullo V
    Cancer Res; 2020 Jun; 80(12):2575-2585. PubMed ID: 32107211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant adenovirus-transduced dendritic cell immunization in a murine model of central nervous system tumor.
    Broder H; Anderson A; Odesa SK; Kremen TJ; Liau LM
    Neurosurg Focus; 2000 Dec; 9(6):e6. PubMed ID: 16817689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
    Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
    Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peptide-loaded Langerhans cells, despite increased IL15 secretion and T-cell activation in vitro, elicit antitumor T-cell responses comparable to peptide-loaded monocyte-derived dendritic cells in vivo.
    Romano E; Rossi M; Ratzinger G; de Cos MA; Chung DJ; Panageas KS; Wolchok JD; Houghton AN; Chapman PB; Heller G; Yuan J; Young JW
    Clin Cancer Res; 2011 Apr; 17(7):1984-97. PubMed ID: 21355077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation.
    Bommareddy PK; Aspromonte S; Zloza A; Rabkin SD; Kaufman HL
    Sci Transl Med; 2018 Dec; 10(471):. PubMed ID: 30541787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytotoxic and immunogenic mechanisms of recombinant oncolytic poliovirus.
    Brown MC; Gromeier M
    Curr Opin Virol; 2015 Aug; 13():81-5. PubMed ID: 26083317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor infection by oncolytic reovirus primes adaptive antitumor immunity.
    Prestwich RJ; Errington F; Ilett EJ; Morgan RS; Scott KJ; Kottke T; Thompson J; Morrison EE; Harrington KJ; Pandha HS; Selby PJ; Vile RG; Melcher AA
    Clin Cancer Res; 2008 Nov; 14(22):7358-66. PubMed ID: 19010851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strategies for antigen loading of dendritic cells to enhance the antitumor immune response.
    Strome SE; Voss S; Wilcox R; Wakefield TL; Tamada K; Flies D; Chapoval A; Lu J; Kasperbauer JL; Padley D; Vile R; Gastineau D; Wettstein P; Chen L
    Cancer Res; 2002 Mar; 62(6):1884-9. PubMed ID: 11912169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A spontaneous multifunctional hydrogel vaccine amplifies the innate immune response to launch a powerful antitumor adaptive immune response.
    Liang X; Li L; Li X; He T; Gong S; Zhu S; Zhang M; Wu Q; Gong C
    Theranostics; 2021; 11(14):6936-6949. PubMed ID: 34093863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.